Dimerix Limited received Australian ethics and regulatory approval for its pivotal Phase 3 clinical trial, ACTION3, to evaluate the efficacy and safety of DMX-200 against a placebo in patients with Focal Segmental Glomerulosclerosis (FSGS) kidney disease. Dimerix anticipates recruitment and screening to commence during the quarter ending December 2021. The single Phase 3 study in FSGS patients has built in two interim analysis points designed to capture evidence of both proteinuria and kidney function (eGFR slope) during the study, aimed at generating sufficient evidence to support accelerated marketing approval. Dimerix has selected more than half of the anticipated approximately 75 global sites across multiple territories to conduct Part 1 of the Phase 3 study (first interim analysis point), five of which are in Australia. Clinical sites will be initiated country by country, based on a number of factors including speed of regulatory and ethics submissions and reviews. Submissions in other territories, including the US nd Europe, are anticipated in the quarter ending December 2021.